| 000 | 01844 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250515200953.0 | ||
| 264 | 0 | _c20110428 | |
| 008 | 201104s 0 0 eng d | ||
| 022 | _a1941-837X | ||
| 024 | 7 |
_a10.3111/13696990903508021 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYuan, Yong | |
| 245 | 0 | 0 |
_aIndirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States. _h[electronic resource] |
| 260 |
_bJournal of medical economics _cMar 2010 |
||
| 300 |
_a33-41 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAbatacept |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xeconomics |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xeconomics |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDisability Evaluation |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHealth Status Indicators |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoconjugates _xeconomics |
| 650 | 0 | 4 |
_aImmunologic Factors _xeconomics |
| 650 | 0 | 4 |
_aMethotrexate _xeconomics |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMonte Carlo Method |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 |
_aRheumatic Fever _xdrug therapy |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aSurveys and Questionnaires |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aTrivedi, Digisha | |
| 700 | 1 | _aMaclean, Ross | |
| 700 | 1 | _aRosenblatt, Lisa | |
| 773 | 0 |
_tJournal of medical economics _gvol. 13 _gno. 1 _gp. 33-41 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3111/13696990903508021 _zAvailable from publisher's website |
| 999 |
_c19383857 _d19383857 |
||